keyword
MENU ▼
Read by QxMD icon Read
search

rheumatoid arthritis remission

keyword
https://www.readbyqxmd.com/read/28431485/efficacy-of-golimumab-in-belgian-patients-with-active-rheumatoid-arthritis-despite-treatment-with-non-biologic-disease-modifying-anti-rheumatic-drugs-sub-analysis-of-the-go-more-study
#1
Patrick Durez, Marie Vanthuyne, Muhammad S Soyfoo, Ilse Hoffman, Michel Malaise, Piet Geusens
OBJECTIVES: The GO-MORE trial (NCT00975130) was a phase 3 study in 40 countries evaluating the efficacy and safety of golimumab as add-on therapy in biologic-naïve adults with active rheumatoid arthritis despite stable treatment with disease-modifying anti-rheumatic drugs. To inform local practice in Belgium and examine the role of baseline disease activity in treatment response, we compared the efficacy of golimumab in the Belgian subpopulation and the rest of the world. METHODS: Baseline disease activity and six-month efficacy rates in the GO-MORE trial were compared for the Belgian subpopulation and the rest of the world by t-tests and chi-squared tests...
April 21, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/28431141/grade-and-location-of-power-doppler-are-predictive-of-damage-progression-in-rheumatoid-arthritis-patients-in-clinical-remission-by-anti-tumour-necrosis-factor-%C3%AE
#2
Bernd Raffeiner, Enrico Grisan, Costantino Botsios, Roberto Stramare, Gaia Rizzo, Livio Bernardi, Leonardo Punzi, Francesca Ometto, Andrea Doria
Objectives.: To investigate power Doppler (PD) signal, grade and location and their association with radiographic progression in RA patients in remission. Methods: . A prospective observational study was conducted in 125 consecutive RA patients in stable 28-joint DAS (DAS28) remission (⩾6 months) achieved on anti-TNF-α. At baseline, patients in stable remission underwent radiographic and US examination of the wrists and MCP, PIP and MTP joints. Semi-quantitative PD scoring (0-3) was recorded...
April 20, 2017: Rheumatology
https://www.readbyqxmd.com/read/28420837/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-with-six-months-of-biological-dmards-treatment
#3
Yusuke Miwa, Ryo Takahashi, Yuzo Ikari, Airi Maeoka, Shinichiro Nishimi, Nao Oguro, Tomoki Hayashi, Mika Hatano, Sakiko Isojima, Ryo Yanai, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki, Kenji Sanada
Objective Although previous studies have reported the prognostic factors for functional remission, no reports have cited the predictive factors. Our aim was to study the predictive factors for functional remission, which is a treatment goal in rheumatoid arthritis (RA), after receiving biological disease-modifying antirheumatic drugs (bDMARDs) treatment for six months. Methods The study consisted of 333 RA patients treated with bDMARDs for six months. The following patient characteristics were investigated: age, gender, disease duration, type of bDMARDs, baseline steroid and methotrexate dosage, and levels of serum rheumatoid factor, matrix metalloprotease, anti-cyclic citrullinated peptides antibody, tumor necrosis factor-α, and interleukin-6...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28420375/silent-progression-in-patients-with-rheumatoid-arthritis-is-das28-remission-an-insufficient-goal-in-ra-results-from-the-german-remission-plus-cohort
#4
Philipp Sewerin, Stefan Vordenbaeumen, Annika Hoyer, Ralph Brinks, Christian Buchbender, Falk Miese, Christoph Schleich, Sabine Klein, Matthias Schneider, Benedikt Ostendorf
BACKGROUND: Remission is arguably the ultimate therapeutic goal in rheumatoid arthritis (RA). Applying modern strategies, clinical remission can be achieved in a substantial number of patients with early RA (ERA). Even in those patients, the number and scope of erosions can increase. We, therefore, investigated the value of MRI for the detection of radiological progression in patients with DAS28 improvement and/or clinical remission of the German Remission-plus cohort. METHODS: Data-sets of 80 RA patients (according to 2010 ACR/EULAR criteria) from the Remission-plus study cohort, who fulfilled the following criteria, were retrospectively analysed: availability of two consecutive MRI scans (low-field MRI, follow-up interval 1 year) of the clinically dominant hand and wrist, and the presence of DAS28 (CRP) scores at both time points, which was used to assess disease activity...
April 19, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28408798/an-open-randomized-active-controlled-clinical-trial-with-low-dose-ska-cytokines-versus-dmards-evaluating-low-disease-activity-maintenance-in-patients-with-rheumatoid-arthritis
#5
L S Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore
BACKGROUND: Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28408110/evaluation-of-the-activity-of-rheumatoid-arthritis-in-clinical-practice-agreement-between-self-rated%C3%A2-clinimetric%C3%A2-evaluation-and-clinical-evaluation-with-activity-indexes-das28-cdai-and-sdai
#6
Gabriel Horta-Baas, Arturo Pérez Bolde-Hernández, María Fernanda Hernández-Cabrera, Imelda Vergara-Sánchez, María Del Socorro Romero-Figueroa
INTRODUCTION AND OBJECTIVE: To achieve control of rheumatoid arthritis (RA) it is necessary to be able to evaluate its activity. The American College of Rheumatology (ACR) recommends for this purpose indexes of activity that can be performed by the patient (PAS-II and RAPID-3) and IA including medical evaluation with laboratory studies (DAS28 and SDAI) or without them (CDAI). The objective was to analyze the concordance between self-rated clinimetric evaluation and clinimetric evaluation performed by the physician...
April 10, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28407999/cost-effectiveness-of-tnf-blocker-injection-spacing-for-patients-with-established-rheumatoid-arthritis-in-remission-an-economic-evaluation-from-the-spacing-of-tnf-blocker-injections-in-rheumatoid-arthritis-trial
#7
RANDOMIZED CONTROLLED TRIAL
Antoine Vanier, Xavier Mariette, Florence Tubach, Bruno Fautrel
BACKGROUND: In patients with rheumatoid arthritis in remission, a disease activity-driven tapering of adalimumab or etanercept relying on progressive injection spacing has not been shown to be equivalent to a maintenance strategy at full dose in terms of disease activity in the Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS) trial. OBJECTIVES: To evaluate the cost-effectiveness of such a spacing strategy based on the data of the STRASS trial...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28407127/no-clear-association-between-ultrasound-remission-and-health-status-in-rheumatoid-arthritis-patients-in-clinical-remission
#8
Myrthe van der Ven, T Martijn Kuijper, Andreas H Gerards, Ilja Tchetverikov, Angelique E Weel, Jendé van Zeben, Johanna M Hazes, Jolanda J Luime
Objectives.: Although RA patients achieve clinical remission, risk of flare still exists. Given the association between US synovitis and increased risk of flare, it is of clinical interest whether these patients report a different health status. Therefore, our aim was to evaluate the frequency of US remission in RA patients in clinical remission and to compare the health status of RA patients in clinical remission with those who were also in US remission. Methods: ...
April 11, 2017: Rheumatology
https://www.readbyqxmd.com/read/28400099/quality-of-life-and-functional-capacity-in-patients-with-rheumatoid-arthritis-cross-sectional-study
#9
Diana Rosa-Gonçalves, Miguel Bernardes, Lúcia Costa
OBJECTIVES: To analyze the Health related Quality of Life (HRQoL) and physical function in rheumatoid arthritis (RA) patients and compare it with the general population. We also intended to analyze about disease activity influence in HRQoL and functional capacity, as well as determine potential determinants for these outcomes. MATERIAL AND METHODS: A cross-sectional study was conducted in RA patients from a university hospital of Portugal. We obtained Short Form 36, EuroQoL 5D, health assessment questionnaire, visual analog scale for pain and patient's assessment of disease activity...
April 8, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28399940/baseline-jak-phosphorylation-profile-of-peripheral-blood-leukocytes-studied-by-whole-blood-phosphospecific-flow-cytometry-is-associated-with-1-year-treatment-response-in-early-rheumatoid-arthritis
#10
Krista Kuuliala, Antti Kuuliala, Riitta Koivuniemi, Hannu Kautiainen, Heikki Repo, Marjatta Leirisalo-Repo
BACKGROUND: We found recently that baseline signal transducer and activator of transcription 3 phosphorylation in peripheral blood CD4(+) T cells of patients with early rheumatoid arthritis (RA) is associated with treatment response to synthetic disease-modifying antirheumatic drugs (DMARDs). This prompted us to study the baseline phosphorylation profiles of Janus kinases (JAKs) in blood leukocytes with respect to treatment response in early RA. METHODS: Thirty-five DMARD-naïve patients with early RA provided blood samples for whole blood flow cytometric determination of phosphorylation of JAKs in CD4(+) and CD8(+) T cells, CD19(+) B cells, and CD14(+) monocytes...
April 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28398409/-macrocytosis-of-red-blood-cells-and-early-arthritis-positive-for-rheumatoid-factor-such-as-initial-manifestations-of-a-neuroendocrine-gastrin-secreting-gastric-tumor
#11
Ciro Manzo, Maria Natale, Gennaro Mossetti, Aniello Piscopo
Neuroendocrine tumors (NETs) represent uncommon tumors arising from the excessive proliferation of enterochromaffin-like (ECL) cells (so-called Kulchitsky cell). Gastric NETs (GNET) represent less than 2% of all NETs and less than 1% of all stomach neoplasms. In particular, gastric NETs type 1 (associated to chronic atrophic gastritis and hypergastrinaemia) is the more frequent one, accounting for 70-80% of all GNET. A macrocytic anemia is a frequent manifestation of GNET type 1. The possibility that macrocytic anemia appear during therapy with methotrexate (MTX) is widely documented...
March 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28395637/safety-and-effectiveness-of-high-dose-methotrexate-over-8%C3%A2-mg-week-in-2838-japanese-patients-with-rheumatoid-arthritis-a-postmarketing-surveillance-report
#12
Yasuo Suzuki, Naonobu Sugiyama, Yuri Fukuma, Noriko Sugiyama, Takeshi Kokubo
OBJECTIVES: To confirm the safety and effectiveness of high-dose (>8 mg/week) methotrexate (MTX) for the treatment of rheumatoid arthritis in Japan. METHODS: A postmarketing surveillance program enrolled Japanese patients with rheumatoid arthritis starting on high-dose MTX followed up for either 24- or 52-weeks. Analyses for safety, risk factors affecting safety, and effectiveness were conducted. RESULTS: The safety/effectiveness analysis sets included 2838/2779 and 335/326 patients in the 24-weeks and 52-weeks follow-up groups, respectively...
April 11, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28389854/a-reduced-12-joint-ultrasound-examination-predicts-lack-of-x-ray-progression-better-than-clinical-remission-criteria-in-patients-with-rheumatoid-arthritis
#13
Eugenio de Miguel, Angela Pecondón-Español, Manuel Castaño-Sánchez, Alfonso Corrales, Ricardo Gutierrez-Polo, Manuel Rodriguez-Gomez, Jose A Pinto-Tasende, Jose L Rivas, José Ivorra-Cortés
To study the predictive value of clinical remission definitions and ultrasound (US) examination on X-ray progression in rheumatoid arthritis (RA). This was an observational prospective multicenter 1-year follow-up cohort of RA patients with moderate disease activity (3.2 < DAS28 ≤ 5.1) who started anti-TNF therapy. DAS28ESR, DAS28CRP, SDAI, CDAI, and ACR/EULAR remission criteria were applied and reduced 12-joint US examination was performed at baseline and at 6 and 12 months. At baseline and month 12, radiographs of hands and feet were obtained in a subset of patients...
April 7, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28389552/tocilizumab-combination-therapy-or-monotherapy-or-methotrexate-monotherapy-in-methotrexate-naive-patients-with-early-rheumatoid-arthritis-2-year-clinical-and-radiographic-results-from-the-randomised-placebo-controlled-function-trial
#14
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan Kay, Andrea Rubbert-Roth, Ricardo Blanco, Alysha Kadva, Sophie Dimonaco
OBJECTIVE: Investigate whether the efficacy and safety of intravenous tocilizumab (TCZ) demonstrated at week 52 in patients with early rheumatoid arthritis (RA) are maintained to week 104. METHODS: Methotrexate (MTX)-naive patients with early progressive RA were randomly assigned to double-blind 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ+placebo or placebo+MTX for 104 weeks. Patients not receiving 8 mg/kg TCZ and not achieving Disease Activity Score-28 joints (DAS28-erythrocyte sedimentation rate (ESR)) ≤3...
April 7, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28388293/long-term-safety-and-effectiveness-of-adalimumab-for-the-treatment-of-japanese-patients-with-rheumatoid-arthritis-3-year-results-from-a-postmarketing-surveillance-of-552-patients
#15
Masayoshi Harigai, Tsuyoshi Tsuchiya, Katsuyoshi Kawana, Sarina Kurimoto
OBJECTIVES: To determine the safety and effectiveness of and identify associated factors in long-term adalimumab (ADA) treatment of Japanese patients with rheumatoid arthritis (RA). METHODS: Of 7740 patients participating in the all-case postmarketing surveillance study, 552 were enrolled in the present study and observed for 3 years. The safety and effectiveness of ADA were analyzed in 509 and 430 patients, respectively. RESULTS: Adverse drug reactions (ADRs) were reported in 34...
April 7, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28380678/clinicopathological-analysis-of-methotrexate-associated-lymphoproliferative-disorders-comparison-of-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma-types
#16
Yuka Gion, Noriko Iwaki, Katsuyoshi Takata, Mai Takeuchi, Keiichiro Nishida, Yorihisa Orita, Tomoyasu Tachibana, Tadashi Yoshino, Yasuharu Sato
Patients with rheumatoid arthritis often develop methotrexate-associated lymphoproliferative disorders (MTX-LPD) during MTX treatment. MTX-LPD occasionally regresses spontaneously after simply discontinuing MTX treatment. In patients without spontaneous regression, additional chemotherapy is required to avoid disease progression. However, the differences between spontaneous and non-spontaneous regression have yet to be elucidated. To clarify the factors important for spontaneous regression, we analyzed the clinicopathological features of 51 patients with rheumatoid arthritis who developed MTX-LPD (diffuse large B-cell lymphoma [DLBCL]-type [n = 34] and classical Hodgkin lymphoma [CHL]-type [n = 17])...
April 5, 2017: Cancer Science
https://www.readbyqxmd.com/read/28376912/head-to-head-comparison-of-aggressive-conventional-therapy-and-three-biological-treatments-and-comparison-of-two-de-escalation-strategies-in-patients-who-respond-to-treatment-study-protocol-for-a-multicenter-randomized-open-label-blinded-assessor-phase-4-study
#17
Daniel Glinatsi, Marte S Heiberg, Anna Rudin, Dan Nordström, Espen A Haavardsholm, Bjorn Gudbjornsson, Mikkel Østergaard, Till Uhlig, Gerdur Grondal, Kim Hørslev-Petersen, Ronald van Vollenhoven, Merete L Hetland
BACKGROUND: New targeted therapies and improved treatment strategies have dramatically improved the outcomes of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can induce stable remission or a low-active disease state that can be maintained with conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The Nordic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) study will assess and compare (1) the proportion of patients who achieve remission in a head-to-head comparison between csDMARD plus glucocorticoid therapy and three different biological DMARD (bDMARD) therapies with different modes of action and (2) two de-escalation strategies in patients who respond to first-line therapy...
April 4, 2017: Trials
https://www.readbyqxmd.com/read/28376060/minimal-disease-activity-in-axial-spondyloarthritis-the-need-of-the-hour-and-a-proposal-for-development
#18
Atul Deodhar, Anand Kumthekar, Maureen Dubreuil
PURPOSE OF REVIEW: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition with articular and extra-articular manifestations. Remission, a state of absence of clinical and imaging signs of disease activity over time, is the goal of management. This review addresses the concept of minimal disease activity (MDA) in axSpA, which is less stringent than remission, and is closer to patient and provider acceptable low disease state. RECENT FINDINGS: Existing axSpA treatments improve physical function and quality of life, and lead to remission in a minority of patients...
April 3, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28371797/real-life-effectiveness-of-golimumab-in-biologic-na%C3%A3-ve-patients-with-rheumatoid-arthritis-data-from-the-rheumatic-diseases-portuguese-register-reuma-pt
#19
Ana Filipa Mourão, Célia Ribeiro, Joana Borges, Maria João Gonçalves, Miguel Bernardes, Susana Fernandes, Raquel Dezerto, Pedro Laires, Patrícia Machado, Mónica Eusébio, Maria José Santos, Helena Canhão
OBJECTIVES: To assess the effectiveness of subcutaneous Golimumab 50 mg/monthly combined with methotrexate (SC GLM + MTX) over 52 weeks of treatment, in biologic-naïve RA patients, in a multicentre nationwide cohort from the Rheumatic Diseases Portuguese Register (Reuma.pt). METHODS: Data for this observational study was collected from March 2011 to August 2015. Disease activity (DAS28), functional capacity (HAQ) and Patient Global Disease Assessment (PGDA) were measured at baseline and weeks 12, 24 and 52 of treatment...
February 18, 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28367894/roles-of-serum-uric-acid-prolactin-levels-and-psychosocial-factors-in-oral-lichen-planus
#20
Akanksha Gupta, Ravi Prakash S Mohan, Swati Gupta, Sangeeta S Malik, Sumit Goel, Nagaraju Kamarthi
Free radicals play important roles in the mechanisms underlying lichen planus (LP). Uric acid (UA) is an important anti-oxidant in plasma. Prolactin (PRL) is an immunomodulatory hormone that may promote LP, as has been documented in other autoimmune disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. PRL has multiple immune-stimulatory effects and promotes the development of such autoimmune disorders. Prolactin and uric acid may serve as biomarkers of disease activity in lichen planus...
2017: Journal of Oral Science
keyword
keyword
52663
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"